Viridian Therapeutics EV To Operating Cash Flow History
| VRDN Stock | USD 27.62 0.64 2.37% |
EV To Operating Cash Flow | First Reported 2010-12-31 | Previous Quarter -8.96 | Current Value -9.41 | Quarterly Volatility 79.0626592 |
Macro event markers
EV To Operating Cash Flow is one of the line items that distinguishes Viridian Therapeutics' financial structure from its peers.
Latest Viridian Therapeutics' EV To Operating Cash Flow Growth Pattern
Viridian Therapeutics's EV To Operating Cash Flow over 14 fiscal periods is shown below. The growing direction is visible across the full charted timeframe. Where the latest reading sits relative to the full range often matters more than the absolute level. The annual reporting cadence smooths out intra-year noise, revealing the underlying direction. Gaps between consecutive data points reveal where Viridian Therapeutics' EV To Operating Cash Flow changed most rapidly.
| EV To Operating Cash Flow | 10 Years Trend |
|
Ev To Operating Cash Flow |
| Timeline |
EV To Operating Cash Flow Trend Statistics
| Arithmetic Mean | -36.99 | |
| Geometric Mean | 8.35 | |
| Coefficient Of Variation | -213.76 | |
| Mean Deviation | 44.26 | |
| Median | -8.39 | |
| Standard Deviation | 79.06 | |
| Sample Variance | 6,251 | |
| Range | 330 | |
| R-Value | 0.47 | |
| Mean Square Error | 5,224 | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | 7.28 | |
| Total Sum of Squares | 100,014 |
Viridian Therapeutics EV To Operating Cash Flow History
| 2026 | -9.41 | ||
| 2025 | -8.96 | ||
| 2024 | -5.26 | ||
| 2023 | -4.85 | ||
| 2022 | -8.39 | ||
| 2021 | -3.55 | ||
| 2020 | -0.44 | ||
| 2019 | 0.0416 | ||
| 2018 | -2.51 | ||
| 2017 | -5.79 | ||
| 2016 | -7.18 | ||
| 2015 | -11.75 | ||
| 2014 | -36.56 | ||
| 2013 | -329.88 |
Related Accounts
| Last Reported | End Of Year Estimate | ||
| Other Operating Expenses | 434.2 M | 456 M | |
| Operating Income | -363.4 M | -345.2 M | |
| Total Operating Expenses | 433.1 M | 454.7 M | |
| Non Operating Income Net Other | 5.4 M | 5.7 M | |
| Total Cash From Operating Activities | -276.4 M | -262.6 M | |
| Change To Operating Activities | 5 M | 5.3 M | |
| Cash Flows Other Operating | -2.9 M | -2.8 M | |
| Operating Cash Flow Per Share | -3.26 | -3.42 | |
| EV To Operating Cash Flow | -8.96 | -9.41 | |
| Operating Cycle | 136.35 | 85.61 | |
| Price To Operating Cash Flows Ratio | -9.55 | -10.03 | |
| Operating Profit Margin | -5.13 | -5.39 | |
| Operating Cash Flow Sales Ratio | -3.90 | -4.10 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.00 | 1.12 |
Methodology, Assumptions & Data Sources
This chart follows Viridian Therapeutics's EV To Operating Cash Flow across recent years. Year-over-year changes are the easiest way to spot turning points.
For Viridian Therapeutics, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Intraday timing differences may exist. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.